Blind faith or regulatory teeth: how can the UK’s regulators stop rising consumer bills?

For millions of consumers across the UK, the findings in this week’s report from the National Audit Office (NAO) would have come as no surprise. Faced with rising costs – resulting for many in rising debt levels – consumers are feeling the pinch in their pockets and an overwhelming feeling they are getting ripped off.Read more

The Week in Brexit: How Meaningful?

Where are we? In fourteen days the UK will leave the European Union, with or without a deal, unless an extension to Article 50 is requested by the UK and granted unanimously by all remaining 27 EU member states. Parliament has instructed the UK government to request an extension, but it has not indicated forRead more

Brexit: what happens next?

Last night Parliament overwhelmingly rejected the slightly revised Withdrawal Agreement put before them by Theresa May. The government was defeated by 149 votes, a narrower margin than the first meaningful vote (230) but still one of the largest defeats by any government in parliamentary history. The Attorney General’s legal opinion that ‘the legal risk remainsRead more

US scrutiny, UK ramifications: pharma pricing in the political spotlight

Pharma companies and their approach to pricing are back in the political spotlight. While there are major differences between US parties on most issues, the debate on drug pricing has united them as last week top executives from seven major pharmaceutical companies were called to testify in front of Congress. A combative session lasted severalRead more